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ABSTRACT
Role of mast cells in allergy had remained undetermined until the discovery of IgE in 1966. Then, IgE purified
from many Liters of plasma, which had been donated from a patient with fatal myeloma, was distributed to re-
searchers all over the world, and thus accelerated exploring the mechanisms involved in allergic reactions, par-
ticularly about the role of mast cells and basophils in the IgE-mediated reactions. Identification of mast cells as
a progeny of a bone marrow hematopoietic stem cell in 1977 led us to successful in vitro culture of human mast
cells. Along with the development of molecular biological techniques, the structure of the high affinity IgE recep-
tor (FcεRI) was determined in 1989. These findings and subsequent investigations brought deeper understand-
ing of IgE-mediated allergic diseases in the past half century, especially where mast cells are involved. We
have now even obtained the information about whole genome expression of FcεRI-dependently activated mast
cells. In sharp contrast to our comprehension of allergic diseases where IgE and mast cells are involved, the
mechanisms involved in non-IgE-mediated allergic diseases or non-IgE-mediated phase of IgE-mediated dis-
eases are almost left unsolved and are waiting for devoted investigators to reveal it.
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INTRODUCTION
Mast cells, presently known as immediate hypersen-
sitivity effector cells, are plentifully found in barrier
tissues connected to the external environment, like
the skin or the mucosa of respiratory and gastrointes-
tinal tracts. Another type of immediate hypersensitiv-
ity effector cells, basophils are circulating in periph-
eral blood as the rarest type of leukocytes. These
cells were first reported by Paul Ehrlich in 18781 and
in 1879,2 respectively. He also observed a phenome-
non that their granules were stained in purple when
blue basic aniline dye was used, and called it metach-
romasia. Later it was found that highly sulfated hepa-
rin proteoglycan present in the granules binds
strongly to basic dyes, polymerizes the basic dye
molecules, and changes the color of dye from blue to
crimson.3 However, the functional properties of these
cells remained enigmatic for a long time.
It took almost a century after discovery of these
cells until we perceived the important role of mast
cells and basophils in allergy. Although this percep-
tion came gradually from many findings, discoveries
of IgE4,5 and its high affinity Fc receptors (FcεRI) on
mast cells6 and basophils7 seem to have affected it de-
cisively. Since then, our knowledge about the role of
mast cells and basophils in allergic diseases has rap-
idly progressed. IgE-sensitized mast cellsbasophils
have been recognized as effector cells which can im-
mediately release a variety of biological mediators
such as histamine or leukotrienes in response to al-
lergen stimulation. We have now identified the whole
mRNA transcripts including all cytokine transcripts
whose levels are changed when the mast cells are ac-
tivated via crosslinking of FcεRI.8 Here, we review
the historical papers regarding the role of mast cells
and basophils in allergy and discuss about the future
perspective of mast cell research.
INVESTIGATION OF MAST CELLS’ ROLE IN
ALLERGIC REACTIONS
Histamine had been suspected to cause anaphylaxis
since 1910,9 although anaphylactic shock was recog-
nized to be associated with a decrease in the hista-
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Fig.　1　First identifi cation of IgE molecules bound to basophils and 
mast cells. Autoradiography of leukocytes (A, B) and sensitized 
monkey skin (C, D) treated with 125I-anti-IgE. Microscope was fo-
cused to grains made by 125I-anti-IgE in (A, C), or to the metachro-
matic granules stained with toluindine blue (B, D). 125I-anti-IgE was 
found to bind only to basophils of the leukocytes and mast cells of 
the skin (A and B were adapted from Fig. 1A, B of the reference 7, 
and C and D were adapted from Fig. 1A, B of the reference 6).
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mine content of the blood at first. This controversy is,
of course, interpreted by the later discovery that his-
tamine is stored in basophils,10 rapidly degenerated
when it is released into blood in vivo, and that baso-
phils release histamine also during serum separation
in vitro as well as allergic reactions in vivo. Soon after
the discovery of histamine in mast cells in 1953,11 rat
mast cells have been reported to release histamine
when stimulated with Compound 4880,12 which has
been known as a histamine liberator.13 Regarding the
role of histamine release in allergic reaction, Lichten-
stein and Osler first demonstrated in 1964 that hista-
mine could be released from human leukocytes ob-
tained from hay fever patients when challenged with
specific antigen in vitro.14
Identification of IgE had been gradually achieved
in 1960s. We (K.I. and T.I.) visualized human IgE for
the first time by precipitation of the protein with the
rabbit antibody specific for human “reagin” (γE) in
agarose gel, and labeled the precipitin band with
radio-labeled ragweed antigen, to which the donors of
the serum was sensitive4 (The method is based on
the same principle to Western blotting, currently em-
ployed). The use of antibodies against unknown pro-
tein seemed the only logical and available method in
1960s, to identify such protein as IgE, of which con-
centration is less than 1 microgram per mL of the se-
rum. Independently, an atypical myeloma protein,
which did not belong to any of the four known immu-
noglobulin isotypes (IgG, IgA, IgM and IgD), was re-
ported by Johansson and Bennich in 1967.5 As the re-
sults of collaboration study, the myeloma protein was
identified as IgE myeloma, as it reacted with the
aforementioned rabbit antibody specific for “regain”,
and IgE was proven to represent a distinct isotype of
immunglobulins.15 After such discoveries of human
IgE,4,5,15 the receptor site of human IgE (FcεRI) was
soon found on human basophils7,16 and on monkey
mast cells6 (Fig. 1). Also, human leukocytes,17 and
later, basophils18 among leukocytes were found to re-
lease histamine in an IgE-dependent manner. Accu-
mulated knowledge regarding molecular characteri-
zation of human IgE let other investigators to dis-
cover IgE of the other species. Then, IgE-sensitized
rat peritoneal mast cells were demonstrated to re-
lease histamine after challenge with allergen.19
Among numerous contributions following IgE dis-
covery, Mr. Peter Shackford’s contribution should be
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remembered. He was admitted to Dartmouth College
Hospital for an unknown type of myeloma in 1968.
The disease turned out to be the second case of IgE
myeloma in the world.20 Then, more than 30 Liters of
his plasma were provided by him by weekly plas-
mapheresis for one year until his death. The
myeloma protein in his plasma was purified by us and
distributed to researchers all over the world. His IgE
(coded as PS-IgE) had been the only human IgE re-
agent available for research, and for the preparation
of anti-IgE in the next 10 years. Even though we
know that plasmapheresis was the only therapeutic
method at that time, we should recognize that Mr.
Shackford gladly consented to our solicitation for us-
ing his plasma to understand the mechanisms in-
volved in “enigmatic” allergic diseases, and that he
knew his life would be soon ended. In this way, he ac-
celerated exploring the mechanisms involved in aller-
gic reactions, especially regarding the role of mast
cells and basophils in the IgE-mediated reac-
tions.6,7,18,21
By 1970, it was generally anticipated that an initial
step of immediate hypersensitivity is a bridging of
mast cell-bound antibody molecules by multivalent
antigen. Requirement of cross-linking of cell-bound
IgE for histamine release was concluded from the fol-
lowing experiments. First, bridging of two cell-bound
IgE molecules by F(ab’)2 fragments of anti-IgE anti-
body was found to induce full reactions such as hista-
mine release.22 Then artificially prepared dimers of
IgE molecules alone were found to induce IgE-
mediated exocytosis.23 However, subsequent studies
revealed that divalent F(ab’)2 fragment of the antibod-
ies against the FcεRI on rat basophilic leukemia
(RBL) cells, but not the monovalent Fab’ fragment of
the antibody, induced histamine release from normal
rat mast cells, indicating that dimerization of the re-
ceptor molecules, rather than polymerization of IgE,
is responsible for the initiation of enzymatic se-
quences in mast cells, leading to the histamine re-
lease.24
Then, Metzger’s group started to identify the struc-
tural features of FcεR by using RBL cells.25 Along
with rapid development of molecular biological tech-
niques, the structure of the FcεRI was finally deter-
mined in 1989 by Metzger and his colleagues.26 Now,
we understand that FcεRI, which is expressed more
than 105 per mast cell or basophil, is a tetrameric
structure comprised of an α chain (FcεRIα) which
binds IgE, a β chain signaling subunit (FcεRIβ), and
two γ subunits existing as a homodimer signaling
subunit (FcεRIγ).27 The molecular cloning of FcεRI as
well as the development of techniques to generate ge-
netically modified mice accelerated our understand-
ing of signal transduction pathway in IgE de-
pendently activated mast cells. Briefly, the crosslink-
ing of FcεRI molecules initiates the association of the
receptor with lipid rafts containing Lyn, a membrane
anchored member of the Src family of protein tyro-
sine kinases. Lyn kinase trans-phosphorylates tyro-
sine residues in the immunoreceptor tyrosine-based
activation motif (ITAM) of FcεRI through the Src ho-
mology 2 (SH2) domain. Syk protein tyrosine kinases
are recruited to the rafts and bind the doubly phos-
phorylated ITAMs. This ITAM phosphorylation in-
duces fully activation of Syk, which initiates a series
of events such as generation of inositol triphosphate
(IP3). Generated IP3 induces Ca2+ mobilization from
its intracellular storage, which results in the influx of
extracellular Ca2+. For FcεRI-dependent activation of
mast cells and basophils, extracellular Ca2+ is abso-
lutely required for the release of both pre-formed
(such as histamine) and newly generated (such as
cysteinyl leukotriene; cys-LT) mediators.28-30 On the
other hand, G-protein-dependent exocytosis of mast
cells or basophils, which can be initiated with com-
pound 4880 or thrombin or formyl peptide, is inde-
pendent from extracellular Ca2+ and the generation of
IP3.31,32
As such, various intracellular signals produced via
aggregation of FcεRI tetramer activate mast cells and
basophils when these cells have been sensitized with
IgE antibody and then are challenged with the aller-
gen. Subsequently, activated mast cells and basophils
can evoke immediate type reaction by releasing their
granules in which histamine, neutral proteases and
heparin had been stored. Then, lipid mediators such
as cys-LT or prostaglandin D2 (PGD2) are synthe-
sized on their membranes and are released into mi-
croenvironment within several minutes.33 Released
histamine and lipid mediators trigger various acute al-
lergic symptoms such as nasal discharge, bron-
chospasms or urticaria. Histamine plays an essential
role in acute skin allergic reactions, whereas cys-LT
plays a pivotal role in bronchoconstriction. Mast cells
exclusively express PGD2 synthase compared to
other cell types. Although the role of PGD2 in imme-
diate type reaction is unclear, it has been reported to
act as a chemoattractant for eosinophils, basophils
and Th2 cells.33
Human mast cells also exclusively express tryp-
tase, one of the neutral proteases, among all human
cell types. Tryptase constitutes 10% of the mast cell
by protein weight.33 Proteoglycan (human mast cells
use “eosinophil” major basic protein instead of pro-
teoglycan molecules) acts as a core protein in the
crystalloid structure of the mast cell granules by
binding to heparin and neutral proteases.8 The mast
cell tryptase serves as trypsin-like enzyme and
thereby causes tissue remodeling such as abnormal
proliferation of airway smooth muscles.34
IN PURSUIT OF MAST CELLS’ ORIGIN AND
CULTURE METHODS
To investigate the mechanisms involved in the IgE-
mediated allergic reactions, a large number of mast
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cells or basophils should be desirably obtained. How-
ever, it came with difficulty for us, especially to obtain
human materials, since basophils are the rarest cell
type among peripheral blood and mast cells dwell
only in the tissue. Thus we, mast cell researchers,
had been struggling to establish the methods of ob-
taining a substantial number of mast cells or baso-
phils.
Ginsburg et al.35 first reported the development of
mast cells in vitro in early 1960s. They found, from
mouse lymph node cells, but not from bone marrow
cells, mast cells grew on fibroblast layers. Since the
identification of mast cells was based only on mor-
phology, controversy occurred as to whether these
cells are really mast cells. Ishizaka et al.36 confirmed
mast cell growth by using a similar system, in long-
term culture of rat thymus cells on fibroblast layers.
They demonstrated the presence of FcεRI on these
cultured “mast” cells in 1976.
These observations can be interpreted by the later
discovery that a very small number of hematopoietic
cells, which should be present even in lymphoid tis-
sues, can develop into mast cells when stimulated
with a lymphocyte-derived mast cell growth factor,
probably interleukin (IL-)3. Fibroblast layers would
have presumably provided growth factors such as kit
ligand (KITLG; formerly called as stem cell factor) to
support the full maturation of mast cells.
As the origin of mast cells, Ehrlich suggested fibro-
blasts present in the connective tissue.1 He could not
imagine, of course, that these cells might derive from
precursors of the hematopoietic lineage. Then after
99 years, Kitamura et al.37 demonstrated hematopoie-
tic stem cells as the origin of mast cells in 1977. They
transplanted bone marrow cells of beige (C57BL-bgJ
bgJ) mice having giant granules in mast cells and
granulocytes into wild type C57BL mice whose bone
marrow precursors had been eliminated by irradia-
tion. They could observe mast cells having giant
granules in the C57BL mice after bone marrow trans-
plantation.37 Kitamura et al. also discovered the two
different mice strains genetically lacking mast cells.
One is SlSld mice38 which are later found to lack
KITLG, and another is WWv mice39 lacking the re-
ceptor for KITLG, called c-Kit or kit. By using these
“natural” mast cell deficient mice, it was established
that mast cells originate from a single hematopoietic
progenitor shared also with granulocytes (Fig. 2).
Then, it was revealed that immature mast cell pro-
genitors migrate from bone marrow into the tissue
through blood circulation, unlike immature granulo-
cytes which are kept in bone marrow.40
Identification of mast cells as a progeny of a hema-
topoietic stem cell enabled us to utilize hematopoietic
tissues for obtaining mast cells. Denburg et al.41 suc-
ceeded to obtain guinea pig basophils (basophils are
a dominant cell type compared to mast cells in guinea
pig) in vitro by culturing bone marrow cells in the
presence of supernatant derived from antigen-
activated lymphocytes in 1980. Then, culture of
mouse mast cells was almost simultaneously reported
by several groups who employed similar methods.
These investigators cultured bone marrow or spleen
hematopoietic cells in the presence of supernatants
derived from antigen-activated lymphocytes.42-44 The
factor that can support murine mast cell growth in vi-
tro was then cloned and termed as IL-3.45
Unlike murine mast cell development, however,
only basophil growth was observed when human he-
matopoietic cells were cultured in the supernatant of
activated lymphocytes.46 Thus the discovery and
cloning of human IL-3 was eagerly expected for cul-
turing human mast cells. Human IL-3 was cloned
based on the sequence of cDNA having a significant
homology to that encoding murine IL-3. However,
even by culturing hematopoietic progenitors with re-
combinant human IL-3, human mast cells did not
grow.47 Thus, successive failures regarding develop-
ment of human mast cells disappointed us.
Although human IL-3 has a significant sequence
homology with murine IL-3, the extent of homology
between human and murine IL-3 (approximately 26-
28% at amino acid sequence) is similarly low com-
pared to that between human IL-3 and granulocyte-
macrophage colony-stimulating factor (GM-CSF).
Furthermore, receptor structure for human IL-3 is
somewhat different from mouse IL-3. The human has
a common β subunit that does not bind any cytokine
by itself but forms high-affinity receptors for GM-
CSF, IL-3, IL-5 with the respective α subunit. In con-
trast, the mouse IL-3 has two distinct β subunits; one
is the counterpart of human common β subunit, and
the other exists only on murine mast cells and binds
only to the murine IL-3 receptor α subunit.48
As has been suggested in the earlier studies,35,36 fi-
broblasts were found to support development of IL-3-
dependetly cultured murine mast cells into the ma-
ture connective-type mast cell phenotype by Levi-
Schaffer et al..49 These authors also reported that ma-
ture human lung mast cells were maintained in vitro
when cocultured with fibroblasts.50 Then, Furitsu et
al.51 succeeded to identify development of human ma-
ture mast cells from hematopoietic cells when cocul-
tured with mouse 3T3 fibroblast cell line in 1989.
In 1990, a fibroblast-derived growth factor for mast
cells was cloned, termed as stem cell factor
(=KITLG), and the results were published almost si-
multaneously in more than 10 original papers by dif-
ferent researchers. While one of these articles was re-
garding cloning of human KITLG,52 mouse or rat
KITLG was found to similarly support human mast
cell development. Even though KITLG supports the
development of human mast cells, a substantial num-
ber of functionally mature mast cells were not always
obtained. In fact, KITLG was found to expand more
hematopoietic stem cells rather than mast cells. It
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Fig.　2　Identifi cation of mast cells as a single hematopoietic cell origin. A 
mixture of bone marrow cells from a beige (bgJ/bgJ) mouse and a wild type 
mouse (+/+) were injected (transplanted) to a wild type mouse who had re-
ceived irradiation to accept donor’s hematopoietic stem cells, which are ca-
pable of forming colonies in spleen. Cells from each hematopoietic cell-de-
rived colony, which grew in the spleen after 12 days, were further 
transplanted into a mast cell-defi cient (W/WV) mouse. Each colony was 
found to have either mast cells having giant granules (beige) or those hav-
ing normal granules (wild-type) after 180 days. Similar results were ob-
tained about granulocyte colonies grown in 8 days of culture; i.e., they were 
either beige or wild-type, and that granule types were always identical be-
tween granulocytes and mast cells. Thus mast cells were demonstrated to 
be derived from a single hematopoietic stem cell capable of producing 
granulocytes.40
bgJ/bgJ (beige)
W/Wv
+/+ (wild type)
+/+
Bone marrows
Spleen
colony
Identification of 
granulocyte type
(beige or wild)
Identification of 
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was also found that IL-6, another fibroblast-derived
factor,53 is capable of supporting the self-renewing of
hematopoietic stem cells as well as KITLG, while
most other cytokines such as GM-CSF suppress it.
Therefore, KITLG and IL-6 were employed for human
mast cell culture.54 IL-6 was later found to stimulate
human mast cell maturation. As such, for preventing
production of stem cell self-renewal-suppressive cy-
tokines such as GM-CSF by macrophages, PGE2,54
methylcellulose culture system (Fig. 3)55 or purifica-
tion of mast cell progenitors56 were used together
with KITLG and IL-6. When highly purified mast cell
progenitors are used, even IL-3 or IL-5 but not GM-
CSF increases the number of cultured mast cells
when cultured together with KITLG and IL-6.56
DISCOVERY OF MAST CELL SUBSETS
Phenotypically distinct subsets of mast cells are pre-
sent in rodents, based on their staining characteris-
tics of their granules, T cell-dependency, and func-
tions, namely connective tissue mast cells, and mu-
cosal mast cells.57,58 In humans, two types of mast
cells have been identified based on the neutral pro-
teases they express. TC-type mast cells (MCTC) con-
tain tryptase together with chymase and other neutral
proteases, whereas T-type mast cells (MCT) contain
only tryptase, but lack the other neutral proteases
present in MCTC.59 MCTC are preferentially found in
the connective tissue such as skin, while MCT are
often found in mucosa such as airway epithelium.
MCTC can respond to various non-immunological
stimuli such as C5a or substance P, while MCT do
not.
Dougherty et al.60 have recently claimed that
asthma can be divided into 2 subgroups based on
characteristic gene expression signatures of epithe-
lial cells; a subgroup (Th2 high asthma) has abun-
dant expression of transcripts for Th2 cytokines such
as IL-13, while the other (Th2 low asthma) almost
lacks it. The patients with Th2 high asthma have
more infiltration of mast cells into the airway epithe-
lium. These intraepithelial mast cells express both
tryptase and carboxypeptidaseA3 (CPA3) but not chy-
mase. According to classical definition,59 MCT were
not supposed to express CPA3. However, based on
our public microarray data (http:www.nch.go.jpim
alGeneChippublic.htm), all types of mast cells and
basophils express the CPA3 transcript. Therefore,
these epithelial mast cells may be equivalent to MCT.
Nevertheless, mast cells exposed to conditioned me-
Saito H et al.
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Fig.　3.　Giant human mast cell colony formed in methylcel-
lulose culture. This picture shows a giant human mast cell 
colony formed in methylcellulose culture, consisting of 
250,000 mast cells. This colony was derived from a single 
CD34+ umbilical cord blood hematopoietic progenitor, which 
is capable of producing 100-fold higher number of mast cells 
compared to adult hematopoietic progenitor in the identical 
culture condition.90
dia from IL-13-activated epithelial cells showed down-
regulation of chymase but no change in tryptase.60
This may relate to the reason why MCT are preferen-
tially found in the mucosa and are deficient in immu-
nodeficiency patients.59 This is contrasting to the re-
sults demonstrating that human mast cell phenotypes
such as chymase expression are retained over weeks
even when these mast cells are cultured in the same
standard methods (supplemented with KITLG and IL-
6).61
DISCOVERY OF MAST CELLS AS SOURCES
OF MULTIPLE CYTOKINES
Mast cells were first reported in 1987 to release some
of cytokines such as tumor necrosis factor (TNF)-α62
or IL-4.63 The discovery of mast cells as sources of
multiple cytokines urged us to investigate the role of
mast cells and basophils in the whole immune system
(Fig. 4). For example, mast cell-derived TNF-α, later
turned out to play significant roles in airway hyperre-
activity, T cell development (enhancement)64 and
bacterial infection (protection).65 Regarding IL-4, a
representative Th2 cytokine production, it seems re-
producibly observed when mouse mast cells are
used. Regarding human mast cells, so far, a few
groups succeeded to immunohistochemically demon-
strate the presence of IL-4 protein in the cells.66,67 At
least in most of human studies, however, basophils
are more potent producers of IL-4, while mast cells
often fail to express IL-4 even upon fierce IgE-
dependent stimulation.68 Interestingly, IL-4 potently
activates human mast cell function and maturation.
By incubating with IL-4 in advance for more than 48
hr, human mast cells become capable of producing
various cytokines including IL-13, another Th2 cy-
tokine, at far more abundant levels in response to
IgE-mediated stimuli.68
Mast cells can secrete a variety of cytokines and
chemokines several hours after IgE-mediated activa-
tion, via transcription of these genes. The representa-
tive cytokineschemokines which are produced by
activated human mast cells are Th2 cytokines such as
IL-5, IL-13 and GM-CSF and CC-chemokines such as
CCL1I-309, CCL2monocyte chemoattractant prote-
in-1, CCL3macrophage inflammatory protein (MIP-)
1α, CCL4MIP-1β. Activated human mast cells also
secrete a substantial amount of CXCL8IL-8.8,68 By
the progress of biological techniques such as mi-
croarray and the mast cell culture method, now we
can discern the big picture of the molecules including
cytokines and chemokines which mast cells can ex-
press in response to IgE-8 and non-IgE-mediated stim-
uli.69
However, these cytokines and chemokines are not
unique to mast cells and are produced by other cell
types. During antigen stimulation, more Th2 cytoki-
nes may be produced by proliferating T cells. It will
be necessary to consider the relative role of mast
cells and basophils in the allergic or innate-type in-
flammation by understanding cytokineschemokines
produced by other immune cell types such as Th2
cells and epithelial-mesenchymal tissues such as
bronchial epithelium. Epithelial-mesenchymal cells
are now considered as a key component of players in
allergic diseases such as asthma, since the structural
change that involves all of the elements of the tissue
should be associated with activation of the epithelial-
mesenchymal trophic unit.70 Activated epithelial-
mesenchymal trophic unit generates a variety of
growth factors related to airway remodeling and cy-
tokines manipulating the immune response such as
IL-33, thymic stromal lymphopoietin (TSLP) and IL-
25. Human mast cells do not normally produce afore-
mentioned Th2 cytokines by only incubating with
other cytokines such as IL-4, unless the cells are acti-
vated via FcεRI crosslinking after the incubation.
However, it should be noted that IL-33, released dur-
ing necrosis of epithelial-mesenchymal tissue, alone
can stimulate mast cells to release a variety of cytoki-
nes such as IL-13. It was only IL-33 that can do so
among 26 cytokines tested.71 It is inferred that mast
cells may initiate inflammation characterized by
eosinophil infiltration and polyclonal IgE production,
by producing cytokines such as IL-13 even where al-
lergens are absent, if IL-33 was released in the tissue.
This may be true for basophils as well.72
UNEXPECTED IDENTIFICATION OF IL33 IN
RELATION TO ALLERGIC DISEASES BY
GWAS
The completion of the Human Genome Project, the
HapMap project,73 and technological advances al-
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Fig.　4.　Infl uences of Th2 cytokines on acute and chronic allergic reactions. In the 
step of allergen sensitization, by the infl uence of environment surrounding the epi-
thelial barrier tissue (such as the presence of TSLP), dendritic cells changes their 
nature to selectively activate Th2 cells. Only in the presence of IL-4 or IL-13, which 
can be produced by Th2 cells, B cells can produce IgE antibody against the aller-
gen. During acute reactions, urticaria, bronchoconstriction and/or hypovolemic 
shock are often induced via release of a variety of mediators from mast cells. During 
chronic reactions, a various symptoms such as grossly-bloody stool (in gastrointes-
tinal allergy) or chronic productive cough (asthma) are caused by infl ammation 
characterized by accumulation of eosinophils. IL-13 seems to play a pivotal role 
both in IgE production (at least in human) and chronic infl ammation. IL-33 may en-
hance this chronic reactions or innate infl ammatory responses independently of IgE 
by enhancing IL-13 production. A recent report indicated that in non-IgE-mediated 
gastrointestinal allergy during infancy, allergen-specifi c Th2 cell activation was con-
fi rmed.91 Since neonatal B cells almost lack IL-4/IL-13 receptors, chronic but not 
acute reactions seem to be observed in their symptoms of food allergy.
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lowed genome-wide association studies (GWAS) to
more comprehensively identify the susceptibility
genes for asthma. Although asthma is now recog-
nized as a syndrome consisting of heterogeneous dis-
ease entities,74 only a few genetic polymorphisms are
constantly found to be susceptible to the general type
of adult asthma in recent large-scale GWAS, i.e., poly-
morphisms in the genes for an epithelial-mesen-
chymal tissue-derived cytokine IL-33 (IL33) andor
its receptor, ST2 (IL1RL1),75-77 while susceptible
genes for atopy (IgE production) were different from
those for asthma.75 Also, using Japanese population,
GWAS identified a polymorphism in ST2 (IL1RL1) as
the most significantly associated with the onset of
atopic dermatitis.78 Thus, IL-33 now attracts much at-
tention among scientists for allergic diseases.
IL-33, a member of the IL-1 cytokine family, is con-
sidered to be crucial for the induction of Th2 cell-
dominant immune responses such as host defense
against nematodes and allergic diseases.79 IL-33 was
originally identified as “DVS27”, a gene up-regulated
in vasospastic cerebral arteries after subarachnoid
hemorrhage80 and as a nuclear factor, “nuclear factor
from high endothelial venules (NF-HEV) ”, which is
expressed in endothelial cell nuclei.81 IL-33 receptor
was first identified as an IL-1 receptor-like molecule
and termed as ST2 (the gene symbol was termed as
IL1RL1) by Tominaga in 1989.82 In 2005, the mole-
cule which had been provisionally termed as DVS27
or NF-HEV, was rediscovered as the 11th member in
the IL-1 family of cytokines, by computationally
searching, and termed as IL-33.83 Human ST2 gene is
preferentially expressed by mast cells and basophils
compared to other leukocytes.84
Using the gene-deficient mice, IL-33 was found to
be more important for innate-type airway inflamma-
Saito H et al.
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tion rather than IgE production in an asthma model.85
Regarding the IL-33-mediated innate-type airway in-
flammation, Lin- c-Kit+ Sca-1+ natural helper cells
dwelling in the gut adipose tissue may play an impor-
tant role.86 Natural helper cells constitutively express
ST2 and can produce a far larger amount of IL-5 and
IL-13 even compared to basophils and mast cells in
response to IL-33, at least in mice.87 The topics re-
garding IL-33 are described in detail elsewhere in this
issue.88
Regarding another topic of non-IgE-mediated
phase of IgE-mediated mast cell activation, histamine
releasing factor present at the site of allergic inflam-
mation has been reported capable of releasing hista-
mine from mast cells by crosslinking IgE-bound
FcεRI on mast cells, via interactions of its N-terminal
and internal regions with the Fab region of IgE.89
This finding is worthy of further investigation.
CONCLUSION - PROBLEMS TO BE SOLVED
IN FUTURE
We may already have comprehended the large part of
IgE-mediated allergic reactions or even IgE-mediated
allergic diseases, particularly regarding mast cell acti-
vation upon allergen challenge. However, the patho-
physiological role of mast cells or other innate inflam-
matory cell types, especially where IgE is not in-
volved, is not yet fully investigated. From the recent
discoveries based on GWAS, it is inferred that “non-
IgE-mediated” innate inflammation plays far more im-
portant role in inflammatory allergic diseases such as
asthma than we previously imagined. It is now re-
quired to investigate the mechanisms involved in
“non-IgE-mediated” phase in mast cell activation and
in allergic diseases.
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